Among top 10 most promising drugs
TSX Exchange Symbol: RVX
CALGARY, July 9 /PRNewswire-FirstCall/ - Resverlogix Corp's ("Resverlogix" or the "Company") (TSX:RVX) novel lead ApoA-I drug candidate, RVX-208 has been selected as one of the top 10 most promising cardiovascular disease (CVD) drugs available for strategic partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
"We are honored to be part of this select group of top ten most promising innovative drugs," stated Donald McCaffrey, President and CEO of Resverlogix. "It again validates RVX-208 and our entire NexVas(TM) PR franchise as an important new small molecule drug for the largest market with unmet needs, atherosclerosis and cardiovascular diseases. We are moving towards our next important milestone, Phase 1b/2a, later this fall and continue to measure safety, tolerability and key reverse cholesterol transport (RCT) markers such as ApoA-I, pre-beta HDL, HDL and cholesterol efflux."
The selection committee was led by Marc Wortman, PhD, contributing writer to Windhover's IN VIVO and Start Up publications, and Michael Rice, Senior Consultant, and Ed Saltzman, President of Defined Health, a leading business development strategy consulting firm. Drawing on the analytic resources of these organizations, the group evaluated hundreds of compounds currently in development for the treatment of cardiovascular disease prior to selecting RVX-208 among the top ten most attractive drug available for partnering.
"Selected companies have been screened using a strict set of judging
criteria for the Top 10 award, and represent what our committee considered
the most attractive cardiovascular opportunities the industry has to
offer," stated Roger Longman, Managing Director of Wi
|SOURCE Resverlogix Corp.|
Copyright©2008 PR Newswire.
All rights reserved